Verastem Inc (NASDAQ:VSTM) was the recipient of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 18,654,118 shares, an increase of 13.1% from the October 15th total of 16,498,651 shares. Based on an average trading volume of 2,428,622 shares, the days-to-cover ratio is currently 7.7 days. Currently, 26.0% of the shares of the company are short sold.
In related news, CEO Robert Forrester bought 10,500 shares of the company’s stock in a transaction on Thursday, September 27th. The shares were purchased at an average cost of $7.00 per share, for a total transaction of $73,500.00. Following the completion of the purchase, the chief executive officer now directly owns 209,234 shares in the company, valued at $1,464,638. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Michael Kauffman bought 4,000 shares of the company’s stock in a transaction on Friday, September 28th. The stock was bought at an average price of $7.49 per share, for a total transaction of $29,960.00. Following the completion of the purchase, the director now owns 4,000 shares of the company’s stock, valued at $29,960. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 19,500 shares of company stock worth $139,420. Corporate insiders own 6.51% of the company’s stock.
Several hedge funds have recently made changes to their positions in VSTM. FMR LLC lifted its stake in shares of Verastem by 2,520.2% during the 2nd quarter. FMR LLC now owns 4,058,097 shares of the biopharmaceutical company’s stock valued at $27,920,000 after buying an additional 3,903,218 shares in the last quarter. BlackRock Inc. lifted its stake in shares of Verastem by 240.6% during the 2nd quarter. BlackRock Inc. now owns 3,542,912 shares of the biopharmaceutical company’s stock valued at $24,376,000 after buying an additional 2,502,853 shares in the last quarter. Northern Trust Corp lifted its stake in shares of Verastem by 558.1% during the 2nd quarter. Northern Trust Corp now owns 625,158 shares of the biopharmaceutical company’s stock valued at $4,301,000 after buying an additional 530,166 shares in the last quarter. EAM Investors LLC purchased a new stake in shares of Verastem during the 2nd quarter valued at approximately $3,288,000. Finally, Bank of New York Mellon Corp lifted its stake in shares of Verastem by 820.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 352,720 shares of the biopharmaceutical company’s stock valued at $2,426,000 after buying an additional 314,401 shares in the last quarter. Institutional investors own 43.40% of the company’s stock.
Verastem (NASDAQ:VSTM) last announced its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.14. The business had revenue of $15.51 million for the quarter. As a group, research analysts forecast that Verastem will post -1.64 EPS for the current year.
A number of research analysts have weighed in on the stock. BidaskClub upgraded shares of Verastem from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, August 28th. HC Wainwright boosted their target price on shares of Verastem to $15.00 and gave the company a “buy” rating in a research note on Tuesday, September 25th. Zacks Investment Research upgraded shares of Verastem from a “hold” rating to a “buy” rating and set a $9.00 target price on the stock in a research note on Friday, July 20th. Raymond James boosted their target price on shares of Verastem from $7.00 to $12.00 in a research note on Friday, August 10th. Finally, BTIG Research assumed coverage on shares of Verastem in a research note on Friday, July 13th. They issued a “buy” rating and a $17.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. Verastem currently has an average rating of “Buy” and a consensus price target of $14.60.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://sportsperspectives.com/2018/11/10/short-interest-in-verastem-inc-vstm-expands-by-13-1.html.
Verastem, Inc, a biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K) signaling pathways. The company's lead FAK inhibitor is defactinib, an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds.
Featured Article: Should You Consider an Index Fund?
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.